BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 15591113)

  • 61. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.
    Lawrie CH; Soneji S; Marafioti T; Cooper CD; Palazzo S; Paterson JC; Cattan H; Enver T; Mager R; Boultwood J; Wainscoat JS; Hatton CS
    Int J Cancer; 2007 Sep; 121(5):1156-61. PubMed ID: 17487835
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
    Rimsza LM; Wright G; Schwartz M; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Cook JR; Tubbs RR; Braziel RM; Delabie J; Miller TP; Staudt LM
    Clin Cancer Res; 2011 Jun; 17(11):3727-32. PubMed ID: 21364035
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.
    Muppidi JR; Schmitz R; Green JA; Xiao W; Larsen AB; Braun SE; An J; Xu Y; Rosenwald A; Ott G; Gascoyne RD; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Vaidehi N; Staudt LM; Cyster JG
    Nature; 2014 Dec; 516(7530):254-8. PubMed ID: 25274307
    [TBL] [Abstract][Full Text] [Related]  

  • 65. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation.
    Natkunam Y; Lossos IS; Taidi B; Zhao S; Lu X; Ding F; Hammer AS; Marafioti T; Byrne GE; Levy S; Warnke RA; Levy R
    Blood; 2005 May; 105(10):3979-86. PubMed ID: 15677569
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
    Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC; Chung Y; Jang S; Park CJ; Chi HS; Huh J; Suh C; Shim H
    Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
    [TBL] [Abstract][Full Text] [Related]  

  • 69. GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas.
    Marcus C; Maragkos GA; Alterman RL; Uhlmann E; Pihan G; Varma H
    J Clin Neurosci; 2021 Jan; 83():49-55. PubMed ID: 33339691
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Germinal center B-cell-like versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL.
    Habara T; Sato Y; Takata K; Iwaki N; Okumura H; Sonobe H; Tanaka T; Orita Y; Abd Al-Kader L; Asano N; Ennishi D; Yoshino T
    J Clin Exp Hematop; 2012; 52(2):91-9. PubMed ID: 23037624
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.
    Huang Q; Liu F; Shen J
    Per Med; 2019 Jul; 16(4):313-323. PubMed ID: 31331250
    [No Abstract]   [Full Text] [Related]  

  • 73. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.
    Lu X; Malumbres R; Shields B; Jiang X; Sarosiek KA; Natkunam Y; Tiganis T; Lossos IS
    Blood; 2008 Nov; 112(10):4098-108. PubMed ID: 18716132
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell.
    Montesinos-Rongen M; Brunn A; Bentink S; Basso K; Lim WK; Klapper W; Schaller C; Reifenberger G; Rubenstein J; Wiestler OD; Spang R; Dalla-Favera R; Siebert R; Deckert M
    Leukemia; 2008 Feb; 22(2):400-5. PubMed ID: 17989719
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
    Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
    Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL.
    Richards KL; Motsinger-Reif AA; Chen HW; Fedoriw Y; Fan C; Nielsen DM; Small GW; Thomas R; Smith C; Dave SS; Perou CM; Breen M; Borst LB; Suter SE
    Cancer Res; 2013 Aug; 73(16):5029-39. PubMed ID: 23783577
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
    Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
    Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.